Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.

Autor: Whiteside D; Department of Neurology, Northwick Park Hospital, London, UK., Barth S; Department of Respiratory Medicine, Northwick Park Hospital, London, UK., Datta A; Department of Respiratory Medicine, Northwick Park Hospital, London, UK., Trip SA; Department of Neurology, Northwick Park Hospital, London, UK; Queen Square MS Centre, National Hospital for Neurology & Neurosurgery, London, UK. Electronic address: anand.trip@nhs.net.
Jazyk: angličtina
Zdroj: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2018 May; Vol. 22, pp. 139-140. Date of Electronic Publication: 2018 Apr 03.
DOI: 10.1016/j.msard.2018.04.002
Abstrakt: The most common adverse events associated with the monoclonal antibody alemtuzumab are infusion associated reactions and secondary autoimmune disease. Respiratory complications are unusual following treatment with alemtuzumab, but can be precipitated by an infectious cause. We describe a case of a sub-acute steroid responsive non-infectious pneumonitis affecting a 51 year old woman, who presented one month after initiation of therapy for multiple sclerosis with alemtuzumab.
(Copyright © 2018 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: